Egetis Therapeutics AB Stock price

Equities

EGTX

SE0003815604

Pharmaceuticals

Market Closed - Nasdaq Stockholm 07:59:36 2024-03-28 am EDT 5-day change 1st Jan Change
6.68 SEK +1.21% Intraday chart for Egetis Therapeutics AB +1.21% +19.71%
Sales 2023 57.6M 5.39M Sales 2024 * 96M 8.98M Capitalization 1.95B 183M
Net income 2023 -327M -30.58M Net income 2024 * -291M -27.21M EV / Sales 2023 25 x
Net cash position 2023 195M 18.2M Net Debt 2024 * 103M 9.59M EV / Sales 2024 * 21.4 x
P/E ratio 2023
-4.29 x
P/E ratio 2024 *
-7.03 x
Employees 29
Yield 2023 *
-
Yield 2024 *
-
Free-Float 72.61%
More Fundamentals * Assessed data
Dynamic Chart
Egetis Therapeutics AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Egetis Therapeutics AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Egetis Therapeutics AB Appoints Laetitia Szaller as General Counsel and Head of Compliance CI
Transcript : Egetis Therapeutics AB - Analyst/Investor Day
Egetis Therapeutics AB Provides Update on Disease Awareness and the Expanded Access Program for Tiratricol in the USA CI
Egetis Therapeutics Grants Fujimoto Pharmaceutical Exclusive Rights to Emcitate in Japan; Stock Rises MT
Egetis Therapeutics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Egetis Therapeutics' Marketing Authorization Application for Emcitate Validated in EU MT
Egetis Therapeutics AB Announces Ema Validation of Marketing Authorisation Application for Emcitate for the Treatment of Mct8 Deficiency CI
Egetis Therapeutics AB Secures Combined Financing of Approximately SEK 462 Million CI
Egetis Therapeutics Raises SEK462 Million Via Private Placement, Debt Financing MT
Egetis Therapeutics Seeks Marketing Authorization for Genetic Disorder Treatment in Europe MT
Egetis Therapeutics AB Submits Marketing Authorisation Application for Emcitate for Treatment of MCT8 Deficiency to the European Medicines Agency CI
Egetis Therapeutics AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Egetis Therapeutics AB Announces First Patient Included and Second Site Activated in the Pivotal Retriact Trial CI
More news

Latest transcript on Egetis Therapeutics AB

1 day+1.21%
1 week+1.21%
Current month+2.61%
1 month+1.21%
3 months+19.71%
6 months+49.94%
Current year+19.71%
More quotes
1 week
6.43
Extreme 6.43
6.74
1 month
5.92
Extreme 5.92
6.94
Current year
5.07
Extreme 5.07
6.94
1 year
3.80
Extreme 3.8
9.20
3 years
3.01
Extreme 3.005
9.20
5 years
3.01
Extreme 3.005
22.30
10 years
3.01
Extreme 3.005
60.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 48 17-06-15
Director of Finance/CFO 45 17-12-30
Chief Tech/Sci/R&D Officer - 22-05-04
Members of the board TitleAgeSince
Chief Tech/Sci/R&D Officer 65 10-06-23
Director/Board Member 59 21-03-31
Director/Board Member 50 19-12-31
More insiders
Date Price Change Volume
24-03-28 6.68 +1.21% 122,236
24-03-27 6.6 +0.15% 180,397
24-03-26 6.59 -1.49% 116,817
24-03-25 6.69 -0.59% 265,282
24-03-22 6.73 +1.97% 267,470

Delayed Quote Nasdaq Stockholm, March 28, 2024 at 07:59 am EDT

More quotes
Egetis Therapeutics AB (publ), formerly PledPharma AB (publ) is a Sweden-based pharmaceutical drug development company, focusing on projects in late-stage development for treatment of diseases with unmet medical needs in the orphan drug segment. The Company's pipeline include Emcitate developed for the treatment of MCT8 deficiency, PledOx developed to reduce nerve damage associated with chemotherapy and Aladote developed to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
6.68 SEK
Average target price
13.12 SEK
Spread / Average Target
+96.48%
Consensus
  1. Stock
  2. Equities
  3. Stock Egetis Therapeutics AB - Nasdaq Stockholm